Development And Evaluation of Mucoadhesive Buccal Tablets for Anti-Diabetic Drugs

The need for alternative drug delivery methods that enhance patient compliance and therapeutic efficacy has been brought to light by the rising incidence of diabetes mellitus and the drawbacks of traditional oral therapy. In order to improve bioavailability by avoiding first-pass metabolism, this study concentrated on the formulation, development, and assessment of mucoadhesive buccal tablets of metformin hydrochloride. Using the direct compression method, five formulations (F1–F5) were created with different concentrations of the mucoadhesive polymers sodium alginate, HPMC, and carbopol 934. Physical characteristics, mucoadhesive strength, swelling index, surface pH, uniformity of drug content, and in-vitro drug release over an 8-hour period were all assessed for the tablets. With the best mechanical strength, the highest mucoadhesion (30.4 g), the most sustained drug release (93.7%), and controlled swelling (68%), formulation F5 outperformed the others. Significant variations between formulations were validated by statistical analysis employing ANOVA and Tukey HSD, confirming the influence of polymer concentration on drug release kinetics. According to the study's findings, mucoadhesive buccal tablets present a viable and patient-friendly substitute for the regulated administration of medications such as metformin hydrochloride, which are used to treat diabetes.